New camera could make cancer treatment safer by better tracking radiation
NCT ID NCT04467567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new type of camera (VERITON-CT) can accurately measure radiation doses in patients receiving Lutathera, a treatment for certain cancers. Fifteen adults were scanned with both the new camera and a standard camera at different times after treatment. The goal was to see if the new camera could provide reliable dose information with fewer scans, which could make the process easier for patients and doctors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lutathera (lutetium Lu 177 dotatate)
- What this could lead to
- If successful, this could lead to a simpler, faster way to measure radiation doses during Lutathera treatment, potentially improving patient safety and treatment planning.
- What could go wrong
- This is a very small, early-stage study (15 people) focused on measurement methods, not treatment outcomes. The new camera may not prove more accurate or practical in routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOSIMETRY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chru Nancy
Vandœuvre-lès-Nancy, 54511, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial
- New imaging agent could sharpen detection of rare tumors